VEA
JAZZ icon

Virtus ETF Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Virtus ETF Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-80
Closed -$8K – 471
2020
Q1 		$8K Sell
80
-2
-2% -$259 ﹤0.01% 403
2019
Q4 		$12K Buy
+82
New +$11.2K ﹤0.01% 428

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Virtus ETF Advisers's JAZZ Position: Q2 2020 in Review

Virtus ETF Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 80 shares — an estimated $8K sold.

Virtus ETF Advisers first reported a position in JAZZ in Q4 2019 and held it in 2 quarters. The position peaked at $12K in Q4 2019. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

  • Virtus ETF Advisers reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 80 Jazz Pharmaceuticals shares in Q2 2020, an estimated $8K.
  • Virtus ETF Advisers first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Virtus ETF Advisers's Jazz Pharmaceuticals position peaked at $12K in Q4 2019.
  • 384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.